Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
NCT05802420Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Open-label trial in pancreatic cancer (PC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05802420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802420.